Pharm (A/Q) Flashcards
Measures the affinity of an enzyme for its substrate ( dec Km = inc affinity)
Km
Maximal velocity of an enzymatic reaction (proportional to enzyme concentration)
Vmax
Does not change Vmax (Lineweaver-Burke lines cross each other “competitively”)
Competitive inhibition
Decreases Vmax (Lineweaver-Burke lines do not cross each other)
Noncompetitive inhibition
Drug in body / plasma drug concentration (low Vd (4-8L: in blood)’ medium Vd (in extracellular space)’ High Vd (> body weight: in tissues))
Volume of Distribution (Vd)
Rate of elimination of drug / plasma drug concentration (OR Vd x Kc’ where Kc is the elimination constant)
Clearance (CL)
T1/2 = (0.7 x Vd) / CL
Half life (t1/2)
1:50%’ 2:75%’ 3:87.5%’ 4:93.75%
Concentration of a substance after X half lives (1’2’3’4)
”= Cp x (Vd / F); (Cp: target plasma conc., F: bioavailability, 1 if by IV)
Loading dose
”= Cp x (CL / F); (Cp: target plasma conc., F: bioavailability, 1 if by IV; a renal patient would have decreased clearance, so they would need a decreased maintenance dose)
Maintenance dose
PEA (phenytoin, ethanol, aspirin)
Common drugs that follow zero-order elimination
Will get trapped in a basic environment, treat with bicarbonate
Treating a weak acid overdose
Will get trapped in an acidic environment, treat with ammonium chloride
Treating a weak base overdose
(Cytochrome P450) 1. reduction, 2. oxidation, 3. hydrolysis (drugs became slightly polarized, may still be active)
Reactions involved in phase I drug metabolism
(Conjugation) 1. acetylation, 2. glucuronidation, 3. sulfonation (drugs become very polarized, are inactivated)
Reactions involved in phase II drug metabolism
Competitive antagonist shifts curve right, requires bigger dose of drug for effect (inc EC50); noncompetitive antagonist shortens curve, cannot reach same level of effect (dec efficacy)
Effect of competitive antagonists on efficacy curves versus noncompetitive antagonists
Partial agonists will have a lower maximal efficacy than full agonists (however potency is independent, they may still be more potent or less potent than a full agonist)
Effect of partial agonists versus full agnoists on efficacy curves
TILE: TI = LD50 / ED50 (median toxic dose / median effective dose; Safer drugs have HIGHER TI values)
Therapeutic index (TI)
Receptor location: NMJ; Function: skeletal muscle contraction; Mechanism: ion channel (Na influx)
Nm receptors
Receptor location: Ganglia; Function: stimulates sympathetics and parasympathetics; Mechanism: ion channel (Na influx);
Nn receptors
Receptor location: Nerve endings; Function: Gastric acid secretion; Mechanism: Gq protein;
M1 receptors
Receptor location: Heart; Function: Inhibitory, reduces heart rate; Mechanism: Gi protein;
M2 receptors
Receptor location: Smooth muscle, endothelium, glands; Function: bronchoconstriction, pupil constriction, accommodation, increases secretions; Mechanism: Gq proteins;
M3 receptors
Receptor location: Arterioles, glands; Function: vasoconstriction, pupillary dilation; Mechanism: Gq protein;
a1
Receptor location: presynaptic nerve endings; Function: inhibitory, feedback inhibition of NT release; Mechanism: Gi protein;
a2
Receptor location: heart, kidney; Function: heart stimulation, renin release; Mechanism: Gs protein;
b1
Receptor location: lungs, skeletal muscle; Function: Vasodilation, bronchiole dilation, ciliary process (makes aqueous humour); Mechanism: Gs protein;
b2
Receptor location: Fat; Function: excitatory; Mechanism: Gs protein;
b3
Function: vasodilation; Mechanism: Gs protein;
D1
Function: Causes NT release in brain; Mechanism: Gi protein;
D2
Function: stimulates mucuous production, bronchiole constriction, pain, itching; Mechanism: Gq protein;
H1
Function: gastric acid secretion; Mechanism: Gs protein;
H2
Function: vasoconstriction; Mechanism: Gq protein;
V1
Function: inc H20 permeability, reabsorption in collecting tubules in kidney; Mechanism: Gs protein;
V2
Sick of sex (SIQ, SQS) D1,D2, H1, H2, V1, V2
Mnemonic for g protein receptors used for D, H, and V receptors
Gq protein activates PLC, IP3 + DAG, inc Ca++ (IP3) and activate PKC (DAG)
Function of Gq protein receptors
Gi protein activates K+ channels, inhibition of adenylate cyclase, reduction of cAMP
Function of Gi protein receptors
Gs protein activates adenylate cyclase, increases cAMP
Function of Gs protein receptors
DUMBBELSS (Diarrhea, urination, miosis, bronchospasm, bradycardia, excitation (of skeletal muscle), lacrimation, sweating, salivation); treatment: atropine (reverses symptoms) + pralidoxime (regenerates cholinesterase)
Symptoms of cholinesterase inhibitor poisoning
Hot as a hare (inc temp), Dry as a bone (dec secretions), Red as a beet (flushed skin), Blind as a bat (cycloplegia), Mad as a hatter
Symptoms of muscarinic antagonist overdose
Bethanechol, carbachol, pilocarpine, methacholine
Direct cholinergic agonist drugs
Bethanechol
Direct cholinergic agonist; activates bowel and bladder post operation
Carbachol
Direct cholinergic agonist; used in glaucoma (causes pupillary contraction and reduces ICP)
Pilocarpine (PILE on the sweat and tears)
Direct cholinergic agonist; potent stimulator of sweat and tears
Methacholine
Direct cholinergic agonist; challenge test for asthma diagnosis
(-stigmine, Ed PHYSted the MAiLman and it ECHOed) Neostigmine, pyridostigmine, physostigmine, edrophonium, echothiophate, malathion
Indirect cholinergic agonist drugs (anticholinesterases)
Neostigmine (NEO CNS)
Indirect cholinergic agonist; used in post operative reversal of NMJ block; does NOT penetrate the CNS
Pyridostigmine
Indirect cholinergic agonist; used for myasthenia gravis (due to it’s long action); does NOT penetrate the CNS
Physostigmine (PHYS is for EYES)
Indirect cholinergic agonist; Used for glaucoma and atropine overdose (does cross CNS)
Edrophonium
Indirect cholinergic agonist; Used to diagnose myasthenia gravis (extremely short action)
Echothiophate
Indirect cholinergic agonist; used for glaucoma
Atropine, homatropine, tropicamide, benztropine, scopolamine, ipratropium, methscopolamine, oxybutynin, glycopyrrolate, pirenzepine, propantheline
Muscarinic antagonist drugs
Atropine (or homatropine, tropicamide)
Muscarinic antagonist drug(s); produces mydriasis and cycloplegia (eye)
Benztropine (PARK my BENZ)
Muscarinic antagonist drug; treatment for parkinson’s (CNS)
Scopolamine
Muscarinic antagonist drug; treatment of motion sickness (CNS)
Ipratropium
Muscarinic antagonist drug; treats asthma and COPD (respiratory)
Methscopolamine (or oxybutynin, glycopyrrolate)
Muscarinic antagonist drug(s); Reduces bladder urgency in cystitis and bladder spasms (GI)
Pirenzepine (or propantheline)
Muscarinic antagonist drug(s); treatment of peptic ulcers (GI)
Atropine
Muscarinic antagonist drug; Used to block DUMBBELSS; Toxicity: hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter
Hexamethonium
Nicotinic antagonist; ganglion blocker, used in experimental models to prevent vaga reflex responses to BP changes
B1
Low doses of epinephrine are selective for what receptor?
Epinephrine
Drug used for anaphylaxis, open angle glaucoma, asthma and hypotension. Binds a1, a2, B1 and B2 receptors.
Norepinephrine
Drug used for hypotension. Binds a1, a2 > B1
Isoproterenol
Drug that binds B1 = B2. Used rarely for AV block
Dopamine
Drug used for shock (by increased renal perfusion), and heart failure. Binds D1 = D2 > B > a.
Dobutamine
Drug used for shock, heart failure, and cardiac stress test. Bind B1 > B2.